Wasaburo Koizumi, Tanabe Satoshi, Higuchi Katsuhiko, Sasaki Toru, Nakayama Norisuke, Mihara Shizuka, Nakatani Kento, Nishimura Ken, Shimoda Takuya, Azuma Mizutomo, Katada Chikatoshi, Hanaoka Noboru, Naruke Akira, Ryu Takahiro, Ishido Kenji, Saigenji Katsunori
Dept. of Gastroenterology and G I Oncology, Kitasato University School of Medicine, Sagamihara, Japan.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:57-63.
The 5-FU plus cisplatin containing regimen like FP, ECF and DCF, is considered to be the most effective treatment for advanced gastric cancer in the United States, Europe, and Korea. In Japan, oral fluoropyrimidine S-1 (TS-1) is currently considered to be the first candidate as the standard drug for advanced gastric cancer. S-1 based combination therapies with other promising drugs like cisplatin, irinotecan and taxanes, are expected to yield good results. Above all, S-1+CDDP therapy showed a high efficacy and expected to be a standard therapy for advanced gastric cancer. Two large phase III studies, JCOG 9912 5-FU vs S-1 vs CPT-11 +CDDP and S-1 vs S-1+CDDP, are now on going to establish an acceptable frontline standard for patients with AGC. We therefore need to develop new agents and combination chemotherapy regimens to achieve a greater survival benefit in AGC.
在美国、欧洲和韩国，含5-氟尿嘧啶和顺铂的方案（如FP、ECF和DCF）被认为是晚期胃癌最有效的治疗方法。在日本，口服氟嘧啶S-1（替吉奥）目前被认为是晚期胃癌标准药物的首选。S-1与顺铂、伊立替康和紫杉烷等其他有前景的药物联合治疗有望取得良好效果。最重要的是，S-1+顺铂疗法显示出高疗效，有望成为晚期胃癌的标准治疗方法。两项大型III期研究，即JCOG 9912（5-氟尿嘧啶对比S-1对比伊立替康+顺铂以及S-1对比S-1+顺铂）正在进行中，以确立可接受的晚期胃癌患者一线标准。因此，我们需要开发新的药物和联合化疗方案，以在晚期胃癌中获得更大的生存益处。
